All In Biotech

Drug Trial Radar · NCT06558344

A Study to Test Different Doses of BI 1569912 in People With Depression

A 6-week, Multi-centre, Randomised, Double-blind (Participant and Investigator), Placebo-controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 in Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Oct 1, 2024

Primary completion

May 2, 2025

Study completion May 12, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants are put into 4 groups randomly, which means by chance. Three of the 4 groups take different doses of BI 1569912 and 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2.5 months. During this time, they visit the study site at least 7 times. At the visits, doctors and their staff ask participants about their depression symptoms. At the end of the study, the results are compared between the groups to see whether the treatment works. The doctors also regularly check the general health of participants and take note of any unwanted effects.

Conditions

  • Depressive Disorder, Major

Interventions

  • 5 mg BI 1569912Drug

    Two 2.5 mg tablets of BI 1569912

  • Placebo matching BI 1569912Drug

    Placebo matching BI 1569912

  • 10 mg BI 1569912Drug

    One 10 mg tablet of BI 1569912

  • 20 mg of BI 1569912Drug

    Two 10 mg tablets of BI 1569912

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in MADRS Total Score at Week 6Time frame: MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.

Locations

41 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Innovations, Inc

    Bellflower, California

  • ASCLEPES Research Centers, P.C. dba Alliance Research

    Long Beach, California

  • Excell Research Inc.

    Oceanside, California

  • CiTrials-Riverside-63180

    Riverside, California

  • Artemis Institute for Clinical Research, LLC

    San Diego, California

  • Lumos Clinical Research

    San Jose, California

  • California Neuroscience Research

    Sherman Oaks, California

  • Pacific Clinical Research Management Group LLC

    Upland, California

  • Research Centers of America-Hollywood-67537

    Hollywood, Florida

  • Clinical Neuroscience Solutions, Inc-Jacksonville-62642

    Jacksonville, Florida

  • CCM Clinical Research Group, LLC-Miami-68482

    Miami, Florida

  • Optimus U Corporation-Miami-69452

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc-Orlando-62685

    Orlando, Florida

  • Advanced Discovery Research LLC

    Atlanta, Georgia

  • iResearch Atlanta

    Decatur, Georgia

  • Psych Atlanta, PC

    Marietta, Georgia

  • Pharmasite Research, Incorporated

    Baltimore, Maryland

  • Copley Clinical

    Boston, Massachusetts

  • Boston Clinical Trials

    Roslindale, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • Psychiatric Care and Research Center

    O'Fallon, Missouri

  • ActivMed

    Portsmouth, New Hampshire

  • Center For Emotional Fitness

    Cherry Hill, New Jersey

  • Bio Behavioral Health

    Toms River, New Jersey

  • Integrative Clinical Trials LLC

    Brooklyn, New York

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York

  • Berman Clinical

    New York, New York

  • Davis Clinical

    The Bronx, New York

  • Sooner Clinical Research, Inc

    Oklahoma City, Oklahoma

  • Surburban Research Associates, Inc.

    Media, Pennsylvania

  • Clinical Neuroscience Solutions, Inc-Memphis-65988

    Memphis, Tennessee

  • FutureSearch Trials of Dallas, LP

    Dallas, Texas

  • Grayline Research Center

    Wichita Falls, Texas

  • Northwest Clinical Research Center

    Bellevue, Washington

  • Core Clinical Research

    Everett, Washington

  • Uematsu Mental Clinic

    Fukuoka, Chikugo, Japan

  • Kaku Mental Clinic

    Fukuoka, Fukuoka, Japan

  • Hirota Clinic

    Fukuoka, Kurume, Japan

  • Yutaka Clinic

    Kanagawa,Sagamihara, Japan

  • Maynds Tower Mental Clinic

    Tokyo, Shibuya-ku, Japan

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.